Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate?

Gut. 2007 Aug;56(8):1086-90. doi: 10.1136/gut.2006.100628. Epub 2006 Nov 24.

Abstract

Background: Branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) of the pancreas are reported to be less aggressive than the main-duct type. Hence, less aggressive treatment has been proposed for the former.

Aim: To evaluate the effectiveness of a follow-up protocol for BD-IPMNs.

Design: Prospective study.

Setting: An academic tertiary referral centre.

Patients: From 2000 to 2003, 109 patients with BD-IPMNs underwent trans-abdominal ultrasound and magnetic resonance cholangiopancreatography with secretin. Patients who presented malignancy-related parameters (size >3.5 cm, nodules, thick walls, carbohydrate antigen 19.9 level >25 U/l, recent-onset or worsened diabetes) and/or complained of symptoms were submitted to surgery (arm A). All asymptomatic patients without suspicion of malignancy were followed up according to a 6-month clinical-radiological protocol (arm B).

Main outcome measures: The effectiveness of conservative management of BD-IPMNs.

Results: 20 (18.3%) patients underwent surgery (arm A); pathological diagnosis of BD-IPMNs was always confirmed. 89 (81.7%) patients were followed up for a median of 32 months (arm B); of these, 57 (64%) patients had multifocal disease. After a mean follow-up of 18.2 months, 5 (5.6%) patients showed an increase in lesion size and underwent surgery. The pathological diagnosis was branch-duct adenoma in three patients and borderline adenoma in two.

Conclusions: Surgery is indicated in <20% of cases of BD-IPMNs, and, in the absence of malignancy-related parameters, careful non-operative management seems to be safe and effective in asymptomatic patients. Although observation for a longer time is needed to confirm these results, our findings support the guidelines recently recommended by the International Association of Pancreatology.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma, Mucinous / diagnostic imaging
  • Adenocarcinoma, Mucinous / surgery
  • Adenocarcinoma, Mucinous / therapy*
  • Adenocarcinoma, Papillary / diagnostic imaging
  • Adenocarcinoma, Papillary / surgery
  • Adenocarcinoma, Papillary / therapy*
  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, Tumor-Associated, Carbohydrate / analysis
  • Carcinoma, Pancreatic Ductal / diagnostic imaging
  • Carcinoma, Pancreatic Ductal / surgery
  • Carcinoma, Pancreatic Ductal / therapy*
  • Cholangiopancreatography, Endoscopic Retrograde / methods
  • Cholangiopancreatography, Magnetic Resonance / methods
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / diagnostic imaging
  • Pancreatic Neoplasms / surgery
  • Pancreatic Neoplasms / therapy*
  • Prospective Studies
  • Treatment Outcome

Substances

  • Antigens, Tumor-Associated, Carbohydrate